Multifamily residents might notice their health improve after living with one of the latest innovations in paint technology. 

Paint Shield, a recently announced product from Sherwin-Williams, is the first EPA-approved microbicidal paint for interior surfaces. 

The coating is proven to continuously kill 99.9% of common, infection-causing bacteria—including Staph (Staphylococcus aureus), MRSA (Methicillin-resistant Staphylococcus aureus), E. coli (Escherichia coli), VRE (Vancomycin-resistant Enterococcus faecalis), and Enterobacter aerogenes—after two hours of exposure on the painted surface. Once two coats of the paint are applied, the product can kill bacteria for up to four years, even after repeated contamination. 

Paint Shield can be used on hard, nonporous ceilings, walls, doors, and trim and is especially suitable for high-traffic buildings—with their concomitant exponential exposure to germs—such as residential multifamily buildings, hotels, schools, and hospitals or healthcare facilities where bacteria are often spread. On average, one in 25 hospital patients will contract a healthcareassociated infection (HAI) during their hospital stay, and HAIs are one of the leading causes of preventable deaths in the United States, according to data from the Centers for Disease Control. 

Paint Shield is a combination of a waterborne latex paint and a proven microbicide with a quaternary ammonium compound that disinfects the surface. The product will be available in the first quarter of 2016 and will come in 590 color options with an eggshell finish. 

“By killing infectious pathogens on painted surfaces, Paint Shield is a game-changing advancement in coatings technology,” says Chris Connor, chairman and chief executive of Sherwin-Williams.